NCER1 Antibody

Definition and Target Specificity

NCoR1 antibodies are immunological tools designed to detect and analyze the Nuclear Receptor Corepressor 1 (NCoR1) protein, a key regulator of gene silencing for unliganded nuclear receptors . These antibodies are typically raised against synthetic peptides corresponding to conserved regions of human NCoR1, such as residues surrounding Pro1387 .

Biological Mechanism of NCoR1

NCoR1 functions as a scaffold protein that recruits chromatin-modifying enzymes (e.g., HDAC3, mSin3) to repress transcription of genes regulated by nuclear receptors like thyroid hormone (THR) and retinoic acid receptors (RAR) . Key structural features include:

• Repression Domains (RDs): Mediate interactions with HDACs and other corepressors.

• SANT Motifs: Enhance HDAC3 activity by recruiting histones .

• CoRNR Boxes: Enable binding to unliganded nuclear receptors .

NCoR1 antibodies enable researchers to study its role in erythropoiesis, thymopoiesis, and hepatic gene regulation, as demonstrated by embryonic lethality in Ncor1-deficient mice .

Key Applications:

• Transcriptional Silencing Studies: Mapping interactions between NCoR1 and nuclear receptors .

• Disease Mechanisms: Dysregulation linked to cancer, diabetes, and cardiovascular disorders .

• Therapeutic Development: Targeting NCoR1 pathways for metabolic and inflammatory diseases .

Validation Data:

Antibody Validation and Performance

The NCoR1 antibody (CAB7046) from Assay Genie has been validated for:

• Specificity: No cross-reactivity with paralog SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptors) .

• Sensitivity: Detects endogenous NCoR1 in human and mouse tissues via Western blot .

Performance Metrics:

Challenges and Future Directions

While NCoR1 antibodies are critical for basic research, challenges persist:

• Batch Variability: Animal-derived antibodies may exhibit inconsistency, prompting calls for non-animal alternatives (e.g., recombinant antibodies) .

• Therapeutic Targeting: No FDA-approved therapies directly modulate NCoR1, though preclinical studies suggest potential in metabolic disorders .